Background: Systemic inflammation is pivotal in the pathogenesis of cardiovascular disease. As inflammation can directly cause cardiomyocyte injury, we hypothesised that established systemic inflammation, as reflected by elevated preoperative neutrophil-lymphocyte ratio (NLR) >4, predisposes patients to perioperative myocardial injury. Methods: We prospectively recruited 1652 patients aged !45 yr who underwent non-cardiac surgery in two UK centres. Serum high sensitivity troponin T (hsTnT) concentrations were measured on the first three postoperative days. Clinicians and investigators were blinded to the troponin results. The primary outcome was perioperative myocardial injury, defined as hsTnT!14 ng L À1 within 3 days after surgery. We assessed whether myocardial injury was associated with
Pathophysiological mechanisms other than ischaemia or thrombosis may contribute to perioperative myocardial injury. In this study, perioperative myocardial injury was associated with systemic inflammation. Relative lymphopaenia and higher concentrations of circulating monocytes may play a mechanistic role.
Asymptomatic myocardial injury occurs in more than 30% of patients undergoing non-cardiac surgery.
1,2 Even apparently minor elevations in troponin are associated with prolonged hospitalisation and higher mortality. The extent and severity of coronary artery disease, however, does not correlate closely with the occurrence of perioperative myocardial injury. 3 Furthermore, pharmacological interventions that are effective in acute coronary syndromes do not prevent myocardial infarction after surgery, 4e6 although longer-term adverse cardiac outcomes may be improved by intensification of medical management for acute coronary syndrome. 7, 8 These data suggest that pathophysiological mechanisms other than ischaemia, thrombosis, or both, may contribute to perioperative myocardial injury. Systemic inflammation plays a major role in the development of cardiovascular disease. 9e11 Inhibition of interleukin (IL)-1b, a cytokine that is pivotal to pro-inflammatory pathways, reduces cardiovascular events in patients with established cardiac disease. 12 Mediators of systemic inflammation directly injure cardiomyocytes, 13 modulate their response to damage, 14, 15 or both. The systemic inflammatory response is an important contributor to myocardial injury, and to damage of other organs, after myocardial infarction and cardiac surgery. The extent to which systemic inflammation is involved in the pathogenesis of myocardial injury after non-cardiac surgery is not known. The neutrophil-lymphocyte ratio (NLR) is a readily available and inexpensive marker of systemic inflammation driven by elevated concentrations of circulating cytokines which have been shown to modulate myocardial injury. 16, 17 NLR enhances the Framingham-based risk prediction of cardiovascular mortality, 18 with higher NLR associated with adverse outcomes after acute coronary syndromes 19 and decompensated heart failure. 20 NLR is also associated with worse perioperative outcomes, 21 albeit for ill-defined, mechanistically unclear reasons. Other leukocyte subsets, including higher monocyte counts, 22 and lower eosinophil counts, 23 may also contribute to the development of cardiovascular morbidity. Here, we hypothesised that the development of perioperative myocardial injury may be modified by mechanisms invoked by systemic inflammation. We assessed prospectively whether systemic inflammation, as reflected by elevated preoperative NLR, leukocyte subsets, or both, implicated in the pathogenesis of cardiomyocyte dysfunction, may promote perioperative myocardial injury. As a further test of this hypothesis, we assessed whether circulating monocytes, which are pivotal for the repair of myocardial injury, generated more injurious reactive oxygen species (ROS) when activated ex vivo in patients with higher NLR.
Methods
We report the results of a prospectively designed substudy from two UK centres which captured leukocyte data where investigators, patients, and healthcare providers were blinded to troponin results throughout the study period. The study was approved by UK National Research Ethics Committee London (MREC:10/WNo03/25). It was conducted in accordance with the principles of the declaration of Helsinki and institutional guidelines. Participants undergoing elective non-cardiac surgery provided written informed consent before surgery.
Participants
Participants were aged 45 yr or older and underwent noncardiac surgery under general or regional anaesthesia at The Royal London Hospital (Barts Health NHS Trust) or at University College Hospital (University College London Hospitals NHS Foundation Trust) who required at least 1 night in hospital after surgery. Participants were excluded if they declined consent or if they had previously enrolled in the VISION study. 1 
Data collection
Researchers collected a detailed and standardised dataset from patients and their medical records, before and during the 30 days after surgery, including postoperative morbidity (defined by PostOperative Morbidity Survey and ClavieneDindo grading). Full definitions of the variables included in this analysis are documented in the Supplementary material. Blood samples were obtained before, between 6 and 12 h after the end of surgery, and on postoperative Days 1, 2, and 3.
Exposures
Leukocyte subsets were measured before operation by observers masked to troponin results (Sysmex XE2100 analyser, Sysmex, Milton Keynes, UK). NLR>4 was defined prospectively as an established median threshold value associated with subclinical inflammation and adverse clinical outcomes derived from studies totalling 40 559 patients. 24 Moreover, a population-based study reported mean NLR 1.76 [95% confidence intervals (CI): 0.83e3.92] in >8500 participants. 25 We assessed the contributions of specific leukocyte subsets to perioperative myocardial injury using absolute counts and thresholds associated with cardiovascular risk in the general cardiovascular literature. Lymphopaenia was defined as <1Â10 9 lymphocytes L À1 . 26 The following thresholds for ab- 
Primary outcome
The primary outcome measure was perioperative myocardial injury defined as serum high sensitivity troponin T (hsTnT) concentration !14 ng L À1 , measured by the hsTnT assay (Elecsys, Roche, Basel, Switzerland) within 3 days after surgery. This hsTnT assay enables the detection of cardiac troponin T at the 99th percentile of an apparently healthy reference population with <10% variability, with a 5 ng L À1 limit of detection. 27 We did not seek to define ischaemic vs non-ischaemic causes of hsTnT elevation, as elevated troponin is linked to poorer clinical outcomes regardless of its aetiology. 28 The secondary clinical outcome was length of hospital stay, stratified by NLR</>4, hsTnT!14 ng L
À1
, or both.
Preoperative monocyte ROS generation
Preoperative monocyte ROS generation was measured by flow cytometry in a subset of 21 patients. Investigators undertaking flow cytometry were masked to NLR values. Monocytes were identified by forward/side scatter characteristics and CD14þ CD16À surface staining ( Supplementary Fig. S1 ). Using fresh whole blood samples obtained before operation, loaded with dihydrorhodamine (DHR)-123 (10 mm), monocyte ROS were quantified after dimethyl sulfoxide (control) or phorbol 12-myristate 13-acetate (PMA) incubation for 10 min at 37 C in a CO 2 incubator (Phagoburst, Orpegen, Heidelberg, Germany).
29
The ROS-reactive dye DHR is converted to cationic green fluorescent rhodamine-123 upon oxidation by PMA, trapping it intracellularly. Median fluorescence intensity was quantified by flow cytometry (CyAn ADP flow cytometer, Beckman Coulter, Wycombe, UK). PMA-induced ROS was expressed as fold-change over each individual's unstimulated (timematched control) sample.
Statistical analysis
The statistical analysis was prospectively planned and registered on a public database (Research Registry:3927 
Sample size estimation
Our previous work in four UK centres showed that preoperative NLR>4 is present in approximately 20% of patients undergoing non-cardiac surgery. 36 Observations from the main VISION study, suggest that~25% of patients develop hsTnT!4 ng L À1 within 72 h after surgery. 1 We therefore estimated that at least 1554 patients would be required to detect a 10% absolute difference in incidence of hsTnT!14 ng L À1 within 72 h after surgery between patients with and without preoperative NLR>4 (a¼0.05; 1-b¼0.9; estimated dropout rate of~7%). For the monocyte ROS experiment, we estimated that a total sample size !19 subjects would be required, assuming a correlation coefficient r¼0.6 (a¼0.05; 1-b¼0.8).
Results
The study included 1682 patients, who were recruited between March 2011 and May 2014 ( Figure 1 ). Preoperative NLR>4 was present in 239 (14.2%) patients ( Supplementary Fig. S2 ). Figure 2 ]. This relationship was similar across surgical subspecialties ( Supplementary Fig. S6 ).
Leukocyte subsets and myocardial injury 
Monocyte ROS generation in relation to preoperative NLR
Clinical characteristics for these patients are shown in Supplementary Table S4 . Higher preoperative NLR was significantly associated with more ROS release from activated monocytes (n¼21 patients; r¼0.47; P¼0.03; Figure 3 ).
Discussion
The principal finding of this prospective observational cohort study involving more than 1600 elective patients undergoing non-cardiac surgery showed that elevated preoperative NLR, which reflects established systemic inflammation, was associated with increased risk of myocardial injury as measured by a high-sensitivity, cardiac-specific troponin assay. Our data implicate specific leukocyte subsets, suggesting that relative lymphopaenia and higher concentrations of circulating monocytes may play a mechanistic role in the development of perioperative myocardial injury. Monocytes, when obtained from patients with higher NLR, generate more injurious ROS when activated ex vivo. Taken together, these data suggest that a common, readily attainable leukocyte-based biomarker indicates that dysregulated inflammation may contribute to perioperative troponin increases. These data reflect the findings of several studies exploring NLR in the cardiovascular literature, although these have primarily focussed on longer term outcomes rather than shortterm risk of cardiac injury. 37 Our data provide further mechanistic insight, as preoperative NLR appears to be associated with a potentially more injurious monocyte phenotype. Murine models of myocardial infarction show that monocytes produced in the bone marrow and spleen are recruited to the injured myocardium in two distinct phases. 38 Within 24 h after myocardial infarction, angiotensin II mediates the release of monocytes from the spleen. The first phase involves B lymphocyte coordinated recruitment of monocytes; depletion of B-cells reduces monocyte infiltration and infarct size. 39 At least in mice, this first phase is characterised by Ly-6c high monocytes which give rise to inflammatory macrophages that clear damaged tissue by phagocytosis and secretion of proteolytic enzymes. This is followed by the infiltration of Ly6c low macrophages that promote wound healing, angiogenesis and myofibroblast differentiation. Mobilisation of circulating monocytes in patients at higher risk of perioperative myocardial injury, that are capable of releasing more injurious ROS, may contribute to more extensive myocardial tissue damage. In contrast, relative higher lymphocyte counts were associated with less myocardial injury. These findings are consistent with previous prospective work we have undertaken showing that lymphopaenia is associated with excess cardiovascular morbidity after elective orthopaedic surgery. 26 Genetic deficiency, or depletion of CD4 þ T-cells impairs wound healing in murine models of myocardial infarction. 40 CD4 þ Tcells modulate monocyte infiltration; their absence increases left ventricular dilatation and mortality after murine myocardial infarction. 41 We have previously shown that lymphopaenia in perioperative patients is characterised by lower T-and B-cell populations, 26 so the relationship between protective T-cell and deleterious B-cell phenotypes requires further elucidation. However, reduced NLR is also associated with poor cardiorespiratory reserve, 36 which may also contribute to perioperative myocardial injury. 42 A strength of our large, prospective, generalisable study is the blinded measurement of hsTnT, an objective biomarker linked to adverse outcome. 1 The exploration of widely available leukocyte measurements adds further generalisability. As causality cannot be inferred from observational data, we are unable to discount that intraoperative management and drug therapy may play an important role in mitigating or exacerbating the influence of chronically elevated systemic inflammation. While the aim of this study was to identify a broadly defined inflammatory phenotype linked to myocardial injury, a further limitation is the lack of additional, integrative functional immune data. Although numbers of circulating leukocytes may correlate with function, they do not necessarily reflect their phenotype at sites of tissue injury. We cannot discount that frailty contributes to poorer outcome, given that in elderly cancer patients, frailty is positively correlated with higher NLR. 43 Similarly, other unmeasured confounders may influence these data. Further investigations are required to establish how a number of inflammatory mechanisms reflected by higher NLR may be involved in perioperative myocardial injury. We have previously shown that nonclassical monocyte subsets, which produce the highest concentrations of inflammatory cytokines in response to tolllike receptor ligands, 44 are more prevalent in patients with higher perioperative risk. 45 Upregulation of endothelial adhesion molecules, chemokines, cytokines, or all three, may promote arrhythmias. 46 Excess inflammation may destabilise atherosclerotic plaques 47 or exacerbate microvascular pathophysiology. 48 In summary, these data provide support for an alternative hypothesis that may, in part, explain the high incidence of perioperative myocardial injury being related to chronically elevated systemic inflammation.
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